| "Euryarchaeota" Woese et al. 1990| Euryarchaeota| Euryarchaeota Garrity and Holt 2002| euryarchaeotes| Methanobacteraeota| Methanobacteraeota Oren et al. 2015| Methanobacteriota
Extreme environments: Many members of the phylum Euryarchaeota thrive in extreme environments characterized by high temperatures, high salinity, high acidity, or high pressure. While these environments are often inhospitable to other forms of life, Euryarchaeota have evolved specialized adaptations to survive and thrive in these conditions. Understanding the biology and biochemistry of Euryarchaeota in extreme environments can provide insights into the limits of life on Earth and the potential for life on other planets.
Methanogenesis: Some Euryarchaeota are capable of methanogenesis, a metabolic process in which methane is produced as a byproduct of anaerobic respiration. Methanogenic archaea play important roles in the carbon cycle, particularly in anaerobic environments such as wetlands, rice paddies, and the digestive tracts of animals. While methane is a potent greenhouse gas, methanogenesis also contributes to the degradation of organic matter and the cycling of nutrients in these ecosystems.
Gut microbiota: Euryarchaeota have been detected in the gastrointestinal tracts of animals, including humans. While their exact roles in the gut microbiota are not well understood, they likely contribute to microbial community dynamics and metabolic processes in the gut. Some studies have suggested associations between the abundance of methanogenic archaea in the gut microbiota and conditions such as obesity, inflammatory bowel disease (IBD), and irritable bowel syndrome (IBS), although the causal relationships are still unclear.
Biotechnological applications: Methanogenic archaea, including some members of Euryarchaeota, have potential biotechnological applications in processes such as anaerobic digestion, wastewater treatment, and biogas production. By converting organic waste materials into methane-rich biogas, methanogenic archaea can contribute to renewable energy production and waste management.
A lot more information is available when you are logged in and raise the display level
Other Sources for more information:
Statistics | NCBI | Data Punk | End Products Produced |
Different labs use different software to read the sample. See this post for more details.
One lab may say you have none, another may say you have a lot! - This may be solely due to the software they are using to estimate.
We deem lab specific values using values from the KM method for each specific lab to be the most reliable.
Lab | Frequency | UD-Low | UD-High | KM Low | KM High | Lab Low | Lab High | Mean | Median | Standard Deviation | Box Plot Low | Box Plot High | KM Percentile Low | KM Percentile High |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Other Labs | 4.15 | 0 | 0 | 1 | 832600 | 0 | 233036 | 28212.2 | 1464 | 104502.1 | 0 | 31630 | 0 %ile | 100 %ile |
biomesight | 25.15 | 0 | 20 | 10 | 8730 | 0 | 10972 | 1473 | 320 | 4846.2 | 0 | 1880 | 0 %ile | 97 %ile |
thorne | 17.24 | 1 | 4 | 0 | 5 | 2.4 | 2 | 1.1 | 1 | 4 | 14.3 %ile | 71.4 %ile | ||
thryve | 23.47 | 0 | 18 | 1 | 5155 | 0 | 17033 | 3424.3 | 740 | 6943.4 | 0 | 5268 | 0 %ile | 92 %ile |
ubiome | 28.9 | 0 | 585 | 21 | 106419 | 0 | 49114 | 13836.8 | 6930 | 17998.8 | 0 | 31720 | 0 %ile | 100 %ile |
Source of Ranges | Low Boundary | High Boundary | Low Boundary %age | High Boundary %age |
---|---|---|---|---|
GanzImmun Diagostics | 0 | 20 | 0 | 0.002 |
Medivere | 0 | 300 | 0 | 0.03 |
Thorne (20/80%ile) | 48.78 | 329.94 | 0.0049 | 0.033 |
Nirvana/CosmosId | 700 | 4700 | 0.07 | 0.47 |
Lab | Frequency Seen | Average | Standard Deviation | Sample Count | Lab Samples |
---|---|---|---|---|---|
AmericanGut | 60 % | 0.107 % | 0.199 % | 9.0 | 15 |
BiomeSight | 26.013 % | 0.13 % | 0.441 % | 745.0 | 2864 |
BiomeSightRdp | 53.125 % | 0.054 % | 0.194 % | 17.0 | 32 |
bugspeak | 100 % | 0.02 % | % | 1.0 | 1 |
CerbaLab | 66.667 % | 0.001 % | 0 % | 2.0 | 3 |
CosmosId | 9.375 % | 0.888 % | 1.035 % | 3.0 | 32 |
custom | 54.237 % | 1.021 % | 0.831 % | 32.0 | 59 |
es-xenogene | 72.414 % | 6.598 % | 21.09 % | 21.0 | 29 |
GanzimmunDiag | 100 % | 0.021 % | 0 % | 3.0 | 3 |
Medivere | 100 % | 0.946 % | 1.934 % | 7.0 | 7 |
Microba | 14.286 % | 1.472 % | 0.768 % | 4.0 | 28 |
Microba1 | 100 % | 2.67 % | % | 1.0 | 1 |
SequentiaBiotech | 52.778 % | 4.894 % | 5.597 % | 19.0 | 36 |
Thorne | 15.909 % | 0.075 % | 0.218 % | 14.0 | 88 |
Thryve | 22.632 % | 0.323 % | 0.679 % | 313.0 | 1383 |
Tiny | 100 % | 0.001 % | % | 1.0 | 1 |
uBiome | 28.914 % | 1.393 % | 1.801 % | 229.0 | 792 |
Click on Impact for information if high or low levels are causing the impact
Magnitude | Impact | Symptom |
---|
|
And display level must be raised above public.
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.